410 related articles for article (PubMed ID: 9787732)
1. Modern medical management of obesity: the role of pharmaceutical intervention.
Aronne LJ
J Am Diet Assoc; 1998 Oct; 98(10 Suppl 2):S23-6. PubMed ID: 9787732
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
[TBL] [Abstract][Full Text] [Related]
4. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
Finer N; James WP; Kopelman PG; Lean ME; Williams G
Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological intervention: the antiobesity approach.
Rissanen A
Eur J Clin Invest; 1998 Sep; 28 Suppl 2():27-30. PubMed ID: 9777325
[TBL] [Abstract][Full Text] [Related]
6. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen AJ; Ernest P
Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
[TBL] [Abstract][Full Text] [Related]
7. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB
JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478
[TBL] [Abstract][Full Text] [Related]
8. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
Sabuncu T; Nazligul Y; Karaoglanoglu M; Ucar E; Kilic FB
Rom J Gastroenterol; 2003 Sep; 12(3):189-92. PubMed ID: 14502318
[TBL] [Abstract][Full Text] [Related]
9. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
10. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacotherapy in the treatment of obesity].
Hamann A
MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.
Douglas IJ; Bhaskaran K; Batterham RL; Smeeth L
Br J Clin Pharmacol; 2015 Jun; 79(6):1020-7. PubMed ID: 25641659
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
[TBL] [Abstract][Full Text] [Related]
14. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
[TBL] [Abstract][Full Text] [Related]
15. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.
Sari R; Balci MK; Cakir M; Altunbas H; Karayalcin U
Endocr Res; 2004 May; 30(2):159-67. PubMed ID: 15473126
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
[TBL] [Abstract][Full Text] [Related]
17. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
Hollander PA; Elbein SC; Hirsch IB; Kelley D; McGill J; Taylor T; Weiss SR; Crockett SE; Kaplan RA; Comstock J; Lucas CP; Lodewick PA; Canovatchel W; Chung J; Hauptman J
Diabetes Care; 1998 Aug; 21(8):1288-94. PubMed ID: 9702435
[TBL] [Abstract][Full Text] [Related]
18. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.
Gursoy A; Erdogan MF; Cin MO; Cesur M; Baskal N
Eat Weight Disord; 2006 Dec; 11(4):e127-32. PubMed ID: 17272944
[TBL] [Abstract][Full Text] [Related]
19. Orlistat and sibutramine beyond weight loss.
Mannucci E; Dicembrini I; Rotella F; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
[TBL] [Abstract][Full Text] [Related]
20. New drug policy in childhood obesity.
Molnár D
Int J Obes (Lond); 2005 Sep; 29 Suppl 2():S62-5. PubMed ID: 16385755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
